Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
206.02
+4.12 (2.04%)
Mar 9, 2026, 2:18 PM EDT - Market open
Ligand Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 268.09 | 167.13 | 131.31 | 196.25 | 241.54 | Upgrade
|
| Revenue Growth (YoY) | 60.40% | 27.28% | -33.09% | -18.75% | 47.68% | Upgrade
|
| Cost of Revenue | 91.44 | 28.96 | 28.8 | 88.91 | 94.28 | Upgrade
|
| Gross Profit | 176.64 | 138.18 | 102.51 | 107.34 | 147.26 | Upgrade
|
| Selling, General & Admin | 92.45 | 78.65 | 52.79 | 70.06 | 46.79 | Upgrade
|
| Research & Development | 4.29 | 3.54 | 6.25 | - | - | Upgrade
|
| Amortization of Goodwill & Intangibles | 32.71 | 32.96 | 33.65 | 34.24 | 34.22 | Upgrade
|
| Operating Expenses | 129.44 | 115.16 | 92.69 | 104.3 | 81.01 | Upgrade
|
| Operating Income | 47.2 | 23.02 | 9.82 | 3.04 | 66.25 | Upgrade
|
| Interest Expense | -4.72 | -3.04 | -0.66 | -1.8 | -19.62 | Upgrade
|
| Interest & Investment Income | 13.66 | 8.06 | 7.71 | 2.05 | 0.89 | Upgrade
|
| Earnings From Equity Investments | 90.66 | -41.6 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.08 | -28.37 | -1.7 | -0.01 | -0.35 | Upgrade
|
| EBT Excluding Unusual Items | 146.72 | -41.93 | 15.17 | 3.28 | 47.17 | Upgrade
|
| Gain (Loss) on Sale of Investments | 18.43 | 75.02 | 46.37 | 28.54 | -5.26 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 2.12 | - | - | Upgrade
|
| Asset Writedown | -6.2 | -30.57 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 4.19 | 30.3 | Upgrade
|
| Pretax Income | 158.96 | 2.52 | 63.66 | 36.01 | 72.21 | Upgrade
|
| Income Tax Expense | 34.51 | 6.55 | 9.84 | 41.23 | -4.15 | Upgrade
|
| Earnings From Continuing Operations | 124.45 | -4.03 | 53.82 | -5.22 | 76.35 | Upgrade
|
| Earnings From Discontinued Operations | - | - | -1.67 | -28.14 | -19.22 | Upgrade
|
| Net Income to Company | 124.45 | -4.03 | 52.15 | -33.36 | 57.14 | Upgrade
|
| Net Income | 124.45 | -4.03 | 52.15 | -33.36 | 57.14 | Upgrade
|
| Net Income to Common | 124.45 | -4.03 | 52.15 | -33.36 | 57.14 | Upgrade
|
| Shares Outstanding (Basic) | 19 | 18 | 17 | 17 | 17 | Upgrade
|
| Shares Outstanding (Diluted) | 20 | 18 | 18 | 17 | 17 | Upgrade
|
| Shares Change (YoY) | 10.96% | 3.00% | 5.27% | -2.19% | 2.50% | Upgrade
|
| EPS (Basic) | 6.44 | -0.22 | 3.02 | -1.98 | 3.44 | Upgrade
|
| EPS (Diluted) | 6.13 | -0.22 | 2.94 | -1.98 | 3.32 | Upgrade
|
| Free Cash Flow | 48.91 | 95.23 | 46.06 | 125.5 | 70.04 | Upgrade
|
| Free Cash Flow Per Share | 2.41 | 5.21 | 2.59 | 7.44 | 4.06 | Upgrade
|
| Gross Margin | 65.89% | 82.67% | 78.07% | 54.70% | 60.97% | Upgrade
|
| Operating Margin | 17.61% | 13.77% | 7.48% | 1.55% | 27.43% | Upgrade
|
| Profit Margin | 46.42% | -2.41% | 39.72% | -17.00% | 23.66% | Upgrade
|
| Free Cash Flow Margin | 18.24% | 56.98% | 35.07% | 63.95% | 29.00% | Upgrade
|
| EBITDA | 80.97 | 58.26 | 46.34 | 41.35 | 117.2 | Upgrade
|
| EBITDA Margin | 30.20% | 34.86% | 35.29% | 21.07% | 48.52% | Upgrade
|
| D&A For EBITDA | 33.78 | 35.24 | 36.52 | 38.32 | 50.95 | Upgrade
|
| EBIT | 47.2 | 23.02 | 9.82 | 3.04 | 66.25 | Upgrade
|
| EBIT Margin | 17.61% | 13.77% | 7.48% | 1.55% | 27.43% | Upgrade
|
| Effective Tax Rate | 21.71% | 260.13% | 15.46% | 114.49% | - | Upgrade
|
| Revenue as Reported | 268.09 | 167.13 | 131.31 | 196.25 | 241.54 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.